Pharmaceutical Bulk Montelukast Sodium Powder

CAS:151767-02-1

MF: C35H37ClNNaO3S

MW:610.18

EINECS:604-813-7

Specification: 99% min Montelukast Sodium Powder

Sample: Montelukast Sodium Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Montelukast Sodium Powder Usage and Synthesis.

Montelukast sodium (montelukastsodium) is a selectively orally administered leukotriene receptor antagonist developed by Merck and marketed in the United States in 1998, which specifically inhibits cysteinyl leukotriene receptors.

It is indicated for the prophylactic and long-term treatment of asthma in adults and children, including the prevention of daytime and nocturnal asthma symptoms, the treatment of aspirin-sensitive asthmatics and the prevention of exercise-induced bronchoconstriction.

Uses and functions of Montelukast Sodium.

Montelukast Sodium Tablets:

1, Prevention and long-term treatment of asthma in adults aged 15 years and older, including prevention of daytime and nighttime asthma symptoms, treatment of aspirin-sensitive asthmatics and prevention of exercise-induced bronchoconstriction.

2.Relief of symptoms caused by seasonal allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in adults aged 15 years and older).

Montelukast Sodium Granules:

For the prophylaxis and long-term treatment of asthma in children aged 1 year and older, including prevention of daytime and nighttime asthma symptoms, treatment of aspirin-sensitive asthmatics and prevention of exercise-induced bronchoconstriction, and alleviation of symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 years and older to 5 years).

Montelukast Sodium Chewable Tablets:

1, This product is indicated for the prevention and long-term treatment of asthma in children aged 2 to 14 years, including the prevention of daytime and nighttime asthma symptoms, the treatment of aspirin-sensitive asthmatics and the prevention of exercise-induced bronchoconstriction.

2.This product is indicated for the relief of symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 to 14 years).

Pharmacological Effects of Montelukast Sodium.

Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released by a wide range of cells, including mast cells and eosinophils, and these important pre-inflammatory mediators of asthma bind to the cysteinyl leukotriene receptor (CysLT) found on the human airway, leading to a variety of airway responses, including bronchoconstriction, mucus secretion, vascular increased permeability and eosinophil aggregation.

Montelukast sodium is an orally effective selective leukotriene receptor antagonist that specifically inhibits cysteinyl leukotriene receptors. It was developed by Merck KGaA, Germany, and launched in Canada, Finland and Mexico in 1997.

It is indicated for the prophylactic and long-term treatment of asthma in adults and children, including the prevention of daytime and nocturnal asthma symptoms, the treatment of patients with aspirin-sensitive asthma and the prevention of exercise-induced bronchoconstriction, and for the relief of the symptoms of seasonal allergic rhinitis in patients 15 years of age and older who are ineffective or intolerant of other treatments they are receiving. Montelukast is a selective leukotriene receptor antagonist approved for the oral treatment of asthma and allergic rhinitis.

It is also a potent oral agent that significantly improves cis-inflammatory markers. Biochemical and pharmacological bioassays have shown that montelukast sodium has a high affinity and selectivity for the CysLT1 receptor (compared to other pharmacologically important airway receptors such as prostaglandin-like, cholinergic and beta-adrenergic receptors).

Montelukast potently inhibits the physiological effects produced by the binding of LTC4, LTD4 and LTE4 to CysLT1 receptors without any receptor agonist activity. A second type of cysteinyl leukotriene receptor (CysLT2) exists in the lung, but may be restricted to the vasculature.

To date, neither receptor has been cloned, so the CysLT receptor profile has been elaborated mainly by receptor binding assays and pharmacological analyses. It is now believed that montelukast sodium does not antagonise the CysLT2 receptor.

Production method of Bulk Montelukast Sodium Powder.

Montelukast is a leukotriene receptor antagonist (LTRA) used for the ongoing treatment of asthma and the relief of seasonal allergy symptoms.

Montelukast blocks the action of leukotriene D4 by binding to the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes, preventing airway oedema, smooth muscle constriction, and thickening of secretory fluid. This reduces leukotriene-induced bronchoconstriction and results in less inflammation.